Trinity Life Sciences Reveals Six Key Global Market Access Trends That Life Sciences Companies Need to Be Monitoring
Trinity Life Sciences Evaluates Commercial Performance Over 3 Years of 58 Novel Drugs Approved in 2020
China’s 2022 NRDL Update Demonstrates Promising Pricing and Access Opportunities for Innovative Drugs With Significant Clinical Benefit
Trinity Life Sciences Maps Out Investment Strategies and Tactics to Calibrate a Patient-Centric Approach in Rare Disease
Trinity Life Sciences Uses New “Tethered” Approach to Integrate HCP-Level Real-World Data and Improve Brand Share Estimates
